Skip to main content

Table 2 Baseline characteristics of our study cohort

From: Association between serum IgG level and clinical course in primary sclerosing cholangitis

  N (%) Median (IQR) Reference values
Gender [Male %] 148 105 (70.9%)  
Median age at initial diagnose [in years] 148 33.5 (26–47)  
Median time of follow-up [in years] 148 9 (3–14)  
Patients diagnosed with AIH/PSC overlap 5 (3.4%)   
Presence of dominate stenosis 87 (58.8%)   
Presence of IBD 99 (66.9%)   
Histopathological proof 65 (43.9%).   
Presence of type I diabetes 4 (2.7%)   
OLT 32 (21.6%)   
Re-OLT 9 (6.1%)   
Death 37 (25%)   
Combined end-point (OLT and death) 57 (38.5%)   
CCA 12 (8.1%)   
Bilirubin [mg/dl] 142 0.8 (0.56–1.6) ─ 1 mg/dl
ALT [IU/l] 145 98.1 (53.5–230.2) ─ 35 IU/l
AST [IU/l] 145 63.5 (32.5–120.5) ─ 37 IU/l
AP [IU/l] 142 265 (151.5–518.0) 40 ─ 130 IU/l
GGT [IU/l] 148 324.0 (151.5–681.5) 6 ─ 26 IU/l
Albumin [g/dl] 137 44.0 (40.0. – 46.0) 30 ─ 50 g/dl
Serum-IgG levels [g/l] 148 14.9 (12.0–20.2) ─ 16 g/l
Mayo risk score 148 −0.2 (−3.1–2.3)  
MELD 142 6 (6–15)  
  1. Abbreviation: AIH/PSC = autoimmune hepatitis/primary sclerosing cholangitis, IBD = inflammatory bowel disease, OLT = orthotopic liver transplantation, CCA = cholangiocarcinoma, ALT = alanine aminotransferase, AST = aspartate aminotransferase, AP = alkaline phosphatase, GGT = y-glutamyl-transferase, MELD score = Model for End-stage Liver Disease